Adult Immunization

Eris, or EG5, is of Omicron lineage and accounts for ~17% of reported COVID-19 cases; mRNA vaccine producers are confident in the new shots to protect against it.

Findings from a new study show the long-term benefits of COVID-19 vaccination to reduce inflammation after a breakthrough infection, say researchers.

CDC immunization recommendations for influenza, COVID-19, and RSV from the updated 2023 schedules are summarized in this Guideline Topline.

A daily dose of clinical news on Patient Care you may have missed.

Which influenza vaccines does CDC recommend for older adults and how do the recommended shots differ from the others available? A short quiz.

You have tens of thousands of dollars worth of vaccines in your office fridge; your area loses power for 5 days after flooding rain. Now what?

The only head-to-head trial of mRNA COVID-19 vaccine safety in older adults finds one has a slight edge over the other, which might just be enough for some patients.

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?

Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.

The arrival of COVID-19 vaccines challenged many people for the first time to understand the actual public health role of vaccination. With the RSV shots, it may be round 2.

The triple assay can identify and differentiate influenza, COVID-19, and respiratory syncytial virus in approximately 2 hours and is already in use.

ACIP guidance on influenza vaccination for the 2023-2024 respiratory virus season includes updates important for primary care clinicians.

The real-world analysis measured the benefit of primary vaccination and of a booster and found the latter dependent upon local disease incidence and risk for severe disease.

For the 25-30 million uninsured adults in the US, the program, which will end in December 2024, will ensure access to protection from the virus for another year.

In the post COVID-19 pandemic health care emergency era, private and public insurance entities will continue full coverage of the shots - but what about the uninsured?

A Vaccines for Adults program was proposed in the 2023 US federal budget and is proposed again for 2024. It is time for a VFA and this slide show highlights why.

The 2 new vaccines are authorized for adults aged 60 years and older and with CDC Director Walensky's final nod, should be available this fall.

Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.

The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.

The FDA advisory committee will review all current surveillance data and recommend which strain/s to include in updated COVID-19 vaccines for the 2023-2024 vaccination campaign.

The FDA has approved 2 vaccines against respiratory syncytial virus in older adults—with final details pending. This 2-question quiz tests how closely you've been following.

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

Medical director of the NFID William Schaffner, MD, shares 3 things about the RSV vaccine that should be top of mind for primary care clinicians.

The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."